Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec;158(6):2675-2687.
doi: 10.1016/j.chest.2020.07.054. Epub 2020 Jul 30.

Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer

Fieke Hoeijmakers  1 , David J Heineman  2 , Johannes M Daniels  3 , Naomi Beck  4 , Rob A E M Tollenaar  4 , Michel W J M Wouters  5 , Perla J Marang-van de Mheen  6 , Wilhelmina H Schreurs  7 ; MDT Study Group
Collaborators, Affiliations

Variation Between Multidisciplinary Tumor Boards in Clinical Staging and Treatment Recommendations for Patients With Locally Advanced Non-small Cell Lung Cancer

Fieke Hoeijmakers et al. Chest. 2020 Dec.

Abstract

Background: Accurate diagnosis and staging are crucial to ensure uniform allocation to the optimal treatment methods for non-small cell lung cancer (NSCLC) patients, but may differ among multidisciplinary tumor boards (MDTs). Discordance between clinical and pathologic TNM stage is particularly important for patients with locally advanced NSCLC (stage IIIA) because it may influence their chance of allocation to curative-intent treatment. We therefore aimed to study agreement on staging and treatment to gain insight into MDT decision-making.

Research question: What is the level of agreement on clinical staging and treatment recommendations among MDTs in stage IIIA NSCLC patients?

Study design and methods: Eleven MDTs each evaluated the same 10 pathologic stage IIIA NSCLC patients in their weekly meeting (n = 110). Patients were selected purposively for their challenging nature. All MDTs received exactly the same clinical information and images per patient. We tested agreement in cT stage, cN stage, cM stage (TNM 8th edition), and treatment proposal among MDTs using Randolph's free-marginal multirater kappa.

Results: Considerable variation among the MDTs was seen in T staging (κ, 0.55 [95% CI, 0.34-0.75]), N staging (κ, 0.59 [95% CI, 0.35-0.83]), overall TNM staging (κ, 0.53 [95% CI, 0.35-0.72]), and treatment recommendations (κ, 0.44 [95% CI, 0.32-0.56]). Most variation in T stage was seen in patients with suspicion of invasion of surrounding structures, which influenced such treatment recommendations as induction therapy and type. For N stage, distinction between N1 and N2 disease was an important source of discordance among MDTs. Variation occurred between 2 patients even regarding M stage. A wide range of additional diagnostics was proposed by the MDTs.

Interpretation: This study demonstrated high variation in staging and treatment of patients with stage IIIA NSCLC among MDTs in different hospitals. Although some variation may be unavoidable in these challenging patients, we should strive for more uniformity.

Keywords: multidisciplinary team; multidisciplinary tumor board; non-small cell lung cancer; staging; treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Example of the clinical information and imaging from one of the patients provided to all MDTs. ECOG = Eastern Cooperative Oncology Group; FDG = fluorodeoxyglucose; MDT = multidisciplinary tumor board.
Figure 2
Figure 2
Staging and treatment tree for patient 1.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization Fact sheet cancer. 2018. https://www.who.int/en/news-room/fact-sheets/detail/cancer World Health Organization website. Accessed April 7, 2020.
    1. Netherlands Comprehensive Cancer Organisation Cijfers over kanker. 2019. https://www.cijfersoverkanker.nl Netherlands Comprehensive Cancer Organisation website. Accessed April 7, 2020.
    1. American Cancer Society Non-small cell lung cancer survival rates. 2019. https://www.cancer.org/cancer/non-small-cell-lung-cancer/detection-diagn... American Cancer Society website. Accessed April 7, 2020.
    1. Lou Y., Dholaria B., Soyano A., Hodge D., Cochuyt J., Manochakian R. Survival trends among non-small-cell lung cancer patients over a decade: impact of initial therapy at academic centers. Cancer Med. 2018;7(10):4932–4942. - PMC - PubMed
    1. Silvestri G.A., Gonzalez A.V., Jantz M.A., Margolis M.L., Gould M.K., Tanoue L.T. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):e211S–e250S. - PubMed

Publication types

MeSH terms